S. Saha, D. Chant, J. Welham, and J. Mcgrath, A Systematic Review of the Prevalence of Schizophrenia, PLOS Med, vol.2, issue.5, p.141, 2005.

J. C. Simeone, A. J. Ward, P. Rotella, J. Collins, and R. Windisch, An evaluation of variation in published estimates of schizophrenia prevalence from 1990?2013: a systematic literature review, BMC Psychiatry, vol.15, p.193, 2015.

C. Murray, A. D. Lopez, W. H. Organization, W. Bank, and . Health, The Global burden of disease : a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 : summary, 1996.

J. Mcgrath, S. Saha, D. Chant, J. Welham, and . Schizophrenia, A Concise Overview of Incidence, Prevalence, and Mortality, Epidemiol Rev, vol.30, issue.1, pp.67-76, 2008.

G. P. Strauss, A. R. Sandt, L. T. Catalano, and D. N. Allen, Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia, Compr Psychiatry, vol.53, issue.8, pp.1137-1181, 2012.

A. Masson, B. Dubois, . Gillain, . Stillemans, . Mahieu et al., Les rechutes psychotiques dans la schizophrénie, Neurone, vol.7, p.6, 2002.

D. A-comparison-of-dsm-iii and . Schizophrenia, Am J Psychiatry, vol.145, issue.11, pp.1446-1455, 1988.

C. Mach and S. Dollfus, Symptômes négatifs de la schizophrénie : une revue des instruments d'évaluation. L'Encéphale, vol.42, pp.165-71, 2016.

S. Dollfus, C. Mach, and R. Morello, Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms, Schizophr Bull, vol.42, issue.3, pp.571-579, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01575633

, Epilepsy : its symptoms, treatment, and relation to other chronic convulsive diseases, pp.1828-1896

:. J. London and . Churchill, , p.1861

H. Spencer, The principles of psychology, p.1895

J. H. Jackson, Remarks on dissolution of the nervous system as exemplified by certain post-epileptic conditions, vol.35, pp.399-402, 1881.

J. Pearce, Positive and negative cerebral symptoms: the roles of Russell Reynolds and Hughlings Jackson, J Neurol Neurosurg Psychiatry, vol.75, issue.8, p.1148, 2004.

. Morel and . Bénédict-augustin, Traité des maladies mentales, p.1860

D. Pringuey, N. Paquin, F. Cherikh, B. Giordana, R. Belzeaux et al.,

. L'encephale, , vol.41, pp.6-9, 2015.

D. Damien,

. Kraepelin-e, Leçons cliniques sur la démence précoce et la psychose maniacodépressive, 1899.

A. Moskowitz and G. Heim, Eugen Bleuler's Dementia Praecox or the Group of Schizophrenias (1911): A Centenary Appreciation and Reconsideration, Schizophr Bull, vol.37, issue.3, pp.471-480, 2011.

J. W. Messinger, F. Trémeau, A. D. Mendelsohn, E. Prudent, V. Stanford et al., Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research, Clin Psychol Rev, vol.31, issue.1, pp.161-169, 2011.

H. Ey, Hughlings jackson's principles and the organo-dynamic concept of psychiatry, Am J Psychiatry, vol.118, issue.8, pp.673-82, 1962.

J. Delay and P. Deniker, Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. International record of medicine and general practice clinics, vol.168, p.318, 1955.

T. J. Crow, Molecular pathology of schizophrenia: more than one disease process?, Br Med J, vol.280, issue.6207, pp.66-74, 1980.

N. C. Andreasen, Negative Symptoms in Schizophrenia: Definition and Reliability. Arch Gen Psychiatry, vol.39, pp.784-792, 1982.

N. C. Andreasen, The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations, Br J Psychiatry Suppl, issue.7, pp.49-58, 1989.

N. C. Andreasen, S. Arndt, D. Miller, M. Flaum, and P. Nopoulos, Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update, Psychopathology, vol.28, issue.1, pp.7-17, 1995.

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-76, 1987.

W. T. Carpenter, D. W. Heinrichs, and A. M. Wagman, Deficit and nondeficit forms of schizophrenia: the concept, Am J Psychiatry, vol.145, issue.5, pp.578-83, 1988.

B. Kirkpatrick, R. W. Buchanan, P. D. Mckenny, L. D. Alphs, and W. T. Carpenter, The schedule for the deficit syndrome: An instrument for research in schizophrenia, Psychiatry Res, vol.30, issue.2, pp.119-142, 1989.

J. M. Ribeyre, S. Dollfus, P. Lesieur, J. F. Ménard, and M. Petit, Schedule for evaluation of the deficit syndrome in schizophrenia: Schedule for Deficit Syndrome (SDS) (Kirkpatrick et al.). Importance pertinence of the SDS

. L'encephale, , vol.20, pp.413-422, 1994.

S. Dollfus, Le traitement des formes déficitaires de schizophrénie. L'Encéphale, vol.33, pp.11-16, 2007.

D. Malaspina, J. Walsh-messinger, W. Gaebel, L. M. Smith, A. Gorun et al., Negative symptoms, past and present: a historical perspective and moving to DSM-5, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.5, pp.710-734, 2014.

B. Kirkpatrick, W. S. Fenton, W. T. Carpenter, and S. R. Marder, The NIMH-MATRICS consensus statement on negative symptoms, Schizophr Bull, vol.32, issue.2, pp.214-223, 2006.

P. D. Harvey, D. Koren, A. Reichenberg, and C. R. Bowie, Negative symptoms and cognitive deficits: what is the nature of their relationship?, Schizophr Bull, vol.32, issue.2, pp.250-258, 2006.

M. F. Green, What are the functional consequences of neurocognitive deficits in schizophrenia?, Am J Psychiatry, vol.153, issue.3, pp.321-351, 1996.

B. Kirkpatrick, R. W. Buchanan, D. E. Ross, and W. T. Carpenter, A separate disease within the syndrome of schizophrenia, Arch Gen Psychiatry, vol.58, issue.2, pp.165-71, 2001.

X. Amador, B. Kirkpatrick, R. Buchanan, W. Carpenter, L. Marcinko et al., Stability of the diagnosis of deficit syndrome in schizophrenia, Am J Psychiatry, vol.156, pp.637-646, 1999.

G. P. Strauss, M. Harrow, L. S. Grossman, and C. Rosen, Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study, Schizophr Bull, vol.36, issue.4, pp.788-99, 2010.

W. Lei, W. Deng, M. Li, Z. He, Y. Han et al., Gray Matter Volume Alterations in Firstepisode Drug-naïve Patients with Deficit and Nondeficit Schizophrenia, Psychiatry Res, vol.234, issue.2, pp.219-245, 2015.

D. Malaspina, E. Coleman, R. R. Goetz, J. Harkavy-friedman, C. Corcoran et al., Odor Identification, Eye Tracking and Deficit Syndrome Schizophrenia, Biol Psychiatry, vol.51, issue.10, pp.809-824, 2002.

M. Beyazyüz, T. Küfeciler, L. Bulut, C. Ünsal, Y. Albayrak et al., Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study, Neuropsychiatr Dis Treat, vol.12, pp.1261-1269, 2016.

X. W. Tang, M. Yu, W. W. Duan, X. R. Zhang, W. W. Sha et al., Facial emotion recognition and alexithymia in Chinese male patients with deficit schizophrenia, Psychiatry Res, vol.246, pp.353-362, 201630.

P. Bucci, A. Mucci, G. Piegari, M. Nobile, S. Pini et al., Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings, Schizophr Res, vol.174, issue.1-3, pp.172-178, 2016.

P. Bucci and S. Galderisi, Categorizing and assessing negative symptoms, Curr Opin Psychiatry, vol.30, issue.3, pp.201-209, 2017.

S. Galderisi, A. Mucci, I. Bitter, J. Libiger, P. Bucci et al., Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.23, issue.3, pp.196-204, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01665221

T. Behdinan, G. Foussias, A. L. Wheeler, L. Stefanik, D. Felsky et al., Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up, Schizophr Res, vol.169, issue.1-3, pp.69-75, 2015.

W. C. Chang, C. Lau, S. Chan, C. Hui, S. Chan et al., Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode psychosis, Psychiatry Res, vol.242, pp.144-153, 201630.

A. Kalisz and A. Cechnicki, The stability of negative syndrome, persistent negative syndrome and deficit syndrome in a twenty-year follow-up study of schizophrenia patients, Psychiatry Res, vol.238, pp.236-277, 2016.

W. T. Carpenter, C. Arango, R. W. Buchanan, and B. Kirkpatrick, Deficit psychopathology and a paradigm shift in schizophrenia research, Biol Psychiatry, vol.46, issue.3, pp.352-60, 1999.

M. J. Millan, K. Fone, T. Steckler, and W. P. Horan, Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment, Eur Neuropsychopharmacol, vol.24, issue.5, pp.645-92, 2014.

M. F. Green, D. L. Penn, R. Bentall, W. T. Carpenter, W. Gaebel et al., Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities, Schizophr Bull, vol.34, issue.6, pp.1211-1231, 2008.

D. M. Barch, J. Bustillo, W. Gaebel, R. Gur, S. Heckers et al., Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5, Schizophr Res, vol.150, issue.1, pp.15-20, 2013.

S. Heckers, D. M. Barch, J. Bustillo, W. Gaebel, R. Gur et al., Structure of the psychotic disorders classification in DSM-5, Schizophr Res, vol.150, issue.1, pp.11-15, 2013.

S. Kaiser, K. Heekeren, and J. J. Simon, The Negative Symptoms of Schizophrenia: Category or Continuum?, Psychopathology, vol.44, issue.6, pp.345-53, 2011.

E. S. Herbener and M. Harrow, Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients, Schizophr Bull, vol.27, issue.3, pp.527-564, 2001.

J. J. Blanchard and A. S. Cohen, The Structure of Negative Symptoms Within Schizophrenia: Implications for Assessment, vol.32, pp.238-283, 2006.

V. Peralta and M. J. Cuesta, Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models, Am J Psychiatry, vol.152, issue.10, pp.1450-1457, 1995.

M. E. Kelley, D. P. Van-kammen, and A. Dn, Empirical validation of primary negative symptoms: independence from effects of medication and psychosis, Am J Psychiatry, vol.156, issue.3, pp.406-417, 1999.

G. Foussias, O. Agid, G. Fervaha, and R. G. , Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.5, pp.693-709, 2014.

D. Mini, Texte imprimé] : critères diagnostiques / American psychiatric association ; coordination générale de la traduction française

G. P. Strauss, W. P. Horan, B. Kirkpatrick, B. A. Fischer, W. R. Keller et al., Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome, J Psychiatr Res, vol.47, issue.6, pp.783-90, 2013.

B. Kirkpatrick, G. P. Strauss, L. Nguyen, B. A. Fischer, D. G. Daniel et al., The brief negative symptom scale: psychometric properties, Schizophr Bull, vol.37, issue.2, pp.300-305, 2011.

A. M. Kring, R. E. Gur, J. J. Blanchard, W. P. Horan, and S. P. Reise, The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation, Am J Psychiatry, vol.170, issue.2, pp.165-72, 2013.

G. Foussias and R. G. , Negative Symptoms in Schizophrenia: Avolition and Occam's Razor, Schizophr Bull, vol.36, issue.2, pp.359-69, 2010.

J. Van-os and K. S. Schizophrenia, Lancet Lond Engl, vol.374, issue.9690, pp.635-680, 2009.

S. Galderisi, A. Mucci, R. W. Buchanan, and C. Arango, Negative symptoms of schizophrenia: new developments and unanswered research questions, Lancet Psychiatry, vol.5, issue.8, pp.664-77, 2018.

H. A. Allen, P. F. Liddle, and C. D. Frith, Negative Features, Retrieval Processes and Verbal Fluency in Schizophrenia, Br J Psychiatry, vol.163, issue.6, pp.769-75, 1993.

C. Sumiyoshi, T. Sumiyoshi, S. Nohara, I. Yamashita, M. Matsui et al., Disorganization of semantic memory underlies alogia in schizophrenia: An analysis of verbal fluency performance in Japanese subjects, Schizophr Res, vol.74, issue.1, pp.91-100, 2005.

A. S. Cohen, J. E. Mcgovern, T. J. Dinzeo, and M. A. Covington, Speech deficits in serious mental illness: a cognitive resource issue? Schizophr Res, vol.160, pp.173-182, 2014.

H. Yazbek, S. Raffard, and J. Del-monte, L'apathie dans la schizophrénie: une revue clinique et critique de la question, Encéphale, vol.pii, issue.13, pp.150-154, 2013.

R. Tandon, W. Gaebel, D. M. Barch, J. Bustillo, R. E. Gur et al., Definition and description of schizophrenia in the DSM-5, Schizophr Res, vol.150, issue.1, pp.3-10, 2013.

, Random House Webster's Unabridged Dictionary, 2006.

G. E. Berrios, The History of Mental Symptoms by

C. Core, , 1996.

R. S. Marin, Apathy: A neuropsychiatric syndrome, J Neuropsychiatry Clin Neurosci, vol.3, issue.3, pp.243-54, 1991.

S. E. Starkstein and A. Leentjens, The nosological position of apathy in clinical practice, J Neurol Neurosurg Psychiatry, vol.79, issue.10, pp.1088-92, 2008.

R. Van-reekum, D. T. Stuss, and L. Ostrander, Apathy: why care?, J Neuropsychiatry Clin Neurosci, vol.17, issue.1, pp.7-19, 2005.

R. S. Marin and P. A. Wilkosz, Disorders of diminished motivation, J Head Trauma Rehabil, vol.20, issue.4, pp.377-88, 2005.

R. Levy and B. Dubois, Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits, Cereb Cortex N Y N, vol.16, issue.7, pp.916-944, 1991.

, Alzheimer et maladies apparentées : diagnostic et prise en charge de l'apathie RECOMMANDATION DE BONNE PRATIQUE -Mis en ligne le 09 oct, 2014.

M. Kiang, B. K. Christensen, R. G. Kapur, and S. , Apathy in schizophrenia: clinical correlates and association with functional outcome, Schizophr Res, vol.63, issue.1-2, pp.79-88, 2003.

J. P. Selten, D. Wiersma, and R. J. Van-den-bosch, Distress attributed to negative symptoms in schizophrenia, Schizophr Bull, vol.26, issue.3, pp.737-781, 2000.

F. Reddy, L. Green, M. F. Rizzo, S. Sugar, C. A. Blanchard et al., Behavioral approach and avoidance in schizophrenia: an evaluation of motivational profiles, Schizophr Res, vol.159, issue.1, pp.164-70, 2014.

D. M. Barch, M. Treadway, and N. Schoen, Effort, Anhedonia, and Function in Schizophrenia: Reduced Effort Allocation Predicts Amotivation and Functional Impairment, J Abnorm Psychol, vol.123, issue.2, pp.387-97, 2014.

G. Fervaha, A. Graff-guerrero, K. K. Zakzanis, G. Foussias, O. Agid et al., Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making, J Psychiatr Res, vol.47, issue.11, pp.1590-1596, 2013.

J. M. Gold, G. P. Strauss, J. A. Waltz, B. M. Robinson, J. K. Brown et al., Negative Symptoms of Schizophrenia Are Associated with Abnormal Effort-Cost Computations, Biol Psychiatry, vol.74, issue.2, pp.130-136, 2013.

C. Prévost, M. Pessiglione, E. Météreau, M. Cléry-melin, and J. Dreher, Separate valuation subsystems for delay and effort decision costs, J Neurosci Off J Soc Neurosci, vol.30, issue.42, pp.14080-90, 2010.

P. E. Meehl, Hedonic capacity: some conjectures, Bull Menninger Clin, vol.39, issue.4, pp.295-307, 1975.

W. P. Horan, A. M. Kring, and J. J. Blanchard, Anhedonia in Schizophrenia: A Review of Assessment Strategies, Schizophr Bull, vol.32, issue.2, pp.259-73, 2006.

J. J. Blanchard, W. P. Horan, and S. A. Brown, Diagnostic differences in social anhedonia: a longitudinal study of schizophrenia and major depressive disorder, J Abnorm Psychol, vol.110, issue.3, pp.363-71, 2001.

K. Llerena, G. P. Strauss, and A. S. Cohen, Looking at the other side of the coin: a meta-analysis of selfreported emotional arousal in people with schizophrenia, Schizophr Res, vol.142, issue.1-3, pp.65-70, 2012.

M. D. Robinson and G. L. Clore, Episodic and semantic knowledge in emotional self-report: evidence for two judgment processes, J Pers Soc Psychol, vol.83, issue.1, pp.198-215, 2002.

C. T. Kollias, V. P. Kontaxakis, B. J. Havaki-kontaxaki, S. Stamouli, M. Margariti et al., Association of physical and social anhedonia with depression in the acute phase of schizophrenia, Psychopathology, vol.41, issue.6, pp.365-70, 2008.

D. E. Gard, A. M. Kring, M. G. Gard, W. P. Horan, and M. F. Green, Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure, Schizophr Res, vol.93, issue.1-3, pp.253-60, 2007.

A. Mucci, D. Dima, A. Soricelli, U. Volpe, P. Bucci et al., Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback, Psychol Med, vol.45, issue.8, pp.1765-78, 2015.

D. M. Barch, D. Pagliaccio, and K. Luking, Mechanisms Underlying Motivational Deficits in Psychopathology: Similarities and Differences in Depression and Schizophrenia, Curr Top Behav Neurosci, vol.27, pp.411-460, 2016.

G. P. Strauss, J. A. Waltz, and J. M. Gold, A review of reward processing and motivational impairment in schizophrenia, Schizophr Bull, vol.40, issue.2, pp.107-116, 2014.

Y. Yang, Z. Yang, Y. Zou, H. Shi, Y. Wang et al., Low-pleasure beliefs in patients with schizophrenia and individuals with social anhedonia, Schizophr Res, 2018.

D. L. Schacter, D. R. Addis, and R. L. Buckner, Remembering the past to imagine the future: the prospective brain, Nat Rev Neurosci, vol.8, issue.9, pp.657-61, 2007.

S. Gallagher and S. Varga, Social cognition and psychopathology: a critical overview, World Psychiatry Off J World Psychiatr Assoc WPA, vol.14, issue.1, pp.5-14, 2015.

C. Lin, C. Huang, Y. Chang, P. Chen, C. Lin et al., Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia, Schizophr Res, vol.146, issue.1-3, pp.231-238, 2013.

J. Archer, D. C. Hay, and A. W. Young, Movement, face processing and schizophrenia: evidence of a differential deficit in expression analysis, Br J Clin Psychol, vol.33, pp.517-545, 1994.

P. W. Corrigan and M. F. Green, Schizophrenic patients' sensitivity to social cues: the role of abstraction, Am J Psychiatry, vol.150, issue.4, pp.589-94, 1993.

M. Cannon, P. Jones, C. Gilvarry, L. Rifkin, K. Mckenzie et al., Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences, Am J Psychiatry, vol.154, issue.11, pp.1544-50, 1997.

S. M. Couture, D. L. Penn, M. Losh, R. Adolphs, R. Hurley et al., Comparison of social cognitive functioning in schizophrenia and high functioning autism: more convergence than divergence, Psychol Med, vol.40, issue.4, pp.569-79, 2010.

A. M. Kring, R. E. Gur, J. J. Blanchard, W. P. Horan, and S. P. Reise, The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation, Am J Psychiatry, vol.170, issue.2, pp.165-72, 2013.

M. J. Sergi, Y. Rassovsky, C. Widmark, C. Reist, S. Erhart et al., Social cognition in schizophrenia: relationships with neurocognition and negative symptoms, Schizophr Res, vol.90, issue.1-3, pp.316-340, 2007.

L. H. Rubin, C. S. Carter, L. Drogos, H. Pournajafi-nazarloo, J. A. Sweeney et al., Peripheral oxytocin is associated with reduced symptom severity in schizophrenia, Schizophr Res, vol.124, issue.1-3, pp.13-21, 2010.

J. D. Henry, M. J. Green, A. De-lucia, C. Restuccia, S. Mcdonald et al., Emotion dysregulation in schizophrenia: reduced amplification of emotional expression is associated with emotional blunting, Schizophr Res, vol.95, issue.1-3, pp.197-204, 2007.

K. Wolf, R. Mass, F. Kiefer, K. Wiedemann, and D. Naber, Characterization of the facial expression of emotions in schizophrenia patients: preliminary findings with a new electromyography method, Can J Psychiatry Rev Can Psychiatr, vol.51, issue.6, pp.335-376, 2006.

K. M. Healey, A. E. Pinkham, J. A. Richard, and C. G. Kohler, Do we recognize facial expressions of emotions from persons with schizophrenia?, Schizophr Res, vol.122, issue.1-3, pp.144-50, 2010.

F. Trémeau, A review of emotion deficits in schizophrenia, Dialogues Clin Neurosci, vol.8, issue.1, pp.59-70, 2006.

A. S. Cohen, J. E. Mcgovern, T. J. Dinzeo, and M. A. Covington, Speech deficits in serious mental illness: a cognitive resource issue? Schizophr Res, vol.160, pp.173-182, 2014.

Z. Kupper, F. Ramseyer, H. Hoffmann, S. Kalbermatten, and W. Tschacher, Video-based quantification of body movement during social interaction indicates the severity of negative symptoms in patients with schizophrenia, Schizophr Res, vol.121, issue.1-3, pp.90-100, 2010.

A. M. Kring and K. S. Earnst, Stability of emotional responding in schizophrenia, Behav Ther, vol.30, issue.3, pp.373-88, 1999.

A. M. Kring and E. K. Moran, Emotional Response Deficits in Schizophrenia: Insights From Affective Science, Schizophr Bull, vol.34, issue.5, pp.819-853, 2008.

R. E. Gur, C. G. Kohler, J. D. Ragland, S. J. Siegel, K. Lesko et al., Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures, Schizophr Bull, vol.32, issue.2, pp.279-87, 2006.

S. Walther, K. Stegmayer, J. Sulzbacher, T. Vanbellingen, R. Müri et al., Nonverbal social communication and gesture control in schizophrenia, Schizophr Bull, vol.41, issue.2, pp.338-383, 2015.

N. N. Boutros, A. Mucci, A. Vignapiano, and S. Galderisi, Electrophysiological aberrations associated with negative symptoms in schizophrenia, Curr Top Behav Neurosci, vol.21, pp.129-56, 2014.

S. Galderisi, M. Quarantelli, U. Volpe, A. Mucci, G. B. Cassano et al., Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia, Schizophr Bull, vol.34, issue.2, pp.393-401, 2008.

P. Brazo, P. Delamillieure, R. Morello, I. Halbecq, R. Marié et al., Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms, Psychiatry Res, vol.133, issue.1, pp.45-55, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00018692

M. Kirschner, A. Aleman, and S. Kaiser, Secondary negative symptoms -A review of mechanisms, assessment and treatment, Schizophr Res, vol.186, pp.29-38, 2017.

G. Fervaha, G. Foussias, O. Agid, and R. G. , Impact of primary negative symptoms on functional outcomes in schizophrenia, Eur Psychiatry J Assoc Eur Psychiatr, vol.29, issue.7, pp.449-55, 2014.

J. C. Jacobsen, G. Maytal, and T. A. Stern, Demoralization in Medical Practice, Prim Care Companion J Clin Psychiatry, vol.9, issue.2, pp.139-182, 2007.

L. Franck and P. Thomas--la-lettre-du-psychiatre, , p.2014

C. D. Marsden and P. Jenner, The pathophysiology of extrapyramidal side-effects of neuroleptic drugs, Psychol Med, vol.10, issue.1, pp.55-72, 1980.

L. Voruganti and A. G. Awad, Neuroleptic dysphoria: towards a new synthesis, Psychopharmacology (Berl), vol.171, issue.2, pp.121-153, 2004.

A. Farreny, M. Savill, and S. Priebe, Correspondence between negative symptoms and potential sources of secondary negative symptoms over time. Eur Arch Psychiatry Clin Neurosci, 2017.

P. F. Buckley, B. J. Miller, D. S. Lehrer, and D. J. Castle, Psychiatric Comorbidities and Schizophrenia, vol.35, pp.383-402, 2009.

I. M. Lako, R. Bruggeman, H. Knegtering, D. Wiersma, R. A. Schoevers et al., A systematic review of instruments to measure depressive symptoms in patients with schizophrenia, J Affect Disord, vol.140, issue.1, pp.38-47, 2012.

D. Addington, J. Addington, and E. Maticka-tyndale, Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry Suppl, pp.39-44, 1993.

A. Gozdzik-zelazny, L. Borecki, and M. Pokorski, Depressive symptoms in schizophrenic patients, Eur J Med Res, vol.16, issue.12, pp.549-52, 2011.

L. Grüber, P. Falkai, and A. Hasan, Depression bei Schizophrenie. Fortschritte Neurol · Psychiatr, vol.83, pp.238-286, 2015.

P. Thomas, A. Amad, and T. Fovet,

. L'encephale, , vol.42, pp.18-22, 2016.

D. A. Regier, M. E. Farmer, D. S. Rae, B. Z. Locke, S. J. Keith et al., Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study, JAMA, vol.264, issue.19, pp.2511-2519, 1990.

A. Dervaux and X. Laqueille, Smoking and schizophrenia: epidemiological and clinical features

. L'encephale, , vol.34, pp.299-305, 2008.

D. J. Kavanagh, J. Mcgrath, J. B. Saunders, G. Dore, and D. Clark, Substance misuse in patients with schizophrenia: epidemiology and management, Drugs, vol.62, issue.5, pp.743-55, 2002.

D. Forti, M. Morgan, C. Dazzan, P. Pariante, C. Mondelli et al., High-potency cannabis and the risk of psychosis, Br J Psychiatry J Ment Sci, vol.195, issue.6, pp.488-91, 2009.

N. G. Toftdahl, M. Nordentoft, and C. Hjorthøj, The Effect of Changes in Cannabis Exposure on Psychotic Symptoms in Patients With Comorbid Cannabis Use Disorder, J Dual Diagn, vol.12, issue.2, pp.129-165, 2016.

L. Dixon, G. Haas, P. J. Weiden, J. Sweeney, and A. J. Frances, Drug abuse in schizophrenic patients: clinical correlates and reasons for use, Am J Psychiatry, vol.148, issue.2, pp.224-254, 1991.

A. Kolliakou, C. Joseph, K. Ismail, Z. Atakan, and R. M. Murray, Why do patients with psychosis use cannabis and are they ready to change their use?, Int J Dev Neurosci, vol.29, issue.3, pp.335-381, 2011.

A. G. Awad and L. Voruganti, Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior, Ther Adv Psychopharmacol, vol.5, issue.3, pp.172-180, 2015.

A. Samaha, Can antipsychotic treatment contribute to drug addiction in schizophrenia?, Prog Neuropsychopharmacol Biol Psychiatry, vol.52, pp.9-16, 2014.

D. F. Duncan, The Acquisition, Maintenance and Treatment of Polydrug Dependence: A Public Health Model, J Psychedelic Drugs, vol.7, issue.2, pp.209-222, 1975.

M. Flaum and N. Andreasen, The reliability of distinguishing primary versus secondary negative symptoms, Compr Psychiatry, vol.36, issue.6, pp.421-428, 1995.

V. Peralta, M. J. Cuesta, A. Martinez-larrea, and J. F. Serrano, Differentiating Primary From Secondary Negative Symptoms in Schizophrenia: A Study of Neuroleptic-Naive Patients Before and After Treatment, Am J Psychiatry, vol.157, issue.9, pp.1461-1467, 2000.

M. Rapado-castro, C. Soutullo, D. Fraguas, C. Arango, B. Payá et al., Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale, J Clin Psychiatry, vol.71, issue.3, pp.327-364, 2010.

M. Krebs, Les symptômes non spécifiques de la transition psychotique. L'Encéphale, vol.37, pp.10-14, 2011.

J. E. Hallak, J. A. Crippa, and G. Vansan, Diagnostic profile of inpatients as a determinant of length of stay in a general hospital psychiatric unit, Braz J Med Biol Res, vol.36, pp.1233-1273, 2003.

D. R. Hopko, D. Lachar, and S. E. Bailley, Assessing predictive factors for extended hospitalization at acute psychiatric admission, Psychiatr Serv, vol.52, pp.1367-73, 2001.

M. Sajatovic, S. H. Friedman, and J. Sabharwal, Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia, J Geriatr Psychiatry Neurol, vol.17, pp.3-8, 2004.

B. Kirkpatrick, A. Kopelowicz, R. W. Buchanan, and W. T. Carpenter, Assessing the efficacy of treatments for the deficit syndrome of schizophrenia, Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.22, issue.3, pp.303-313, 2000.

S. Leucht, C. Corves, D. Arbter, R. R. Engel, C. Li et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet Lond Engl, vol.373, issue.9657, pp.31-41, 2009.

J. A. Lieberman, Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia, J Clin Psychiatry, vol.60, pp.9-12, 1999.

A. Lobos, C. Komossa, K. Rummel-kluge, C. Hunger, H. Schmid et al., Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, p.6633, 2010.

R. C. Harvey, A. C. James, and G. E. Shields, A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia, CNS Drugs, vol.30, issue.1, pp.27-39, 2016.

P. Fusar-poli, E. Papanastasiou, D. Stahl, M. Rocchetti, W. Carpenter et al., Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials, Schizophr Bull, vol.41, issue.4, pp.892-901, 2015.

P. Falkai, T. Wobrock-d-med, J. Lieberman, B. Glenthoj, W. F. Gattaz et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia, World J Biol Psychiatry, vol.6, issue.3, pp.132-91, 2005.

S. Leucht, Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials, Int J Neuropsychopharmacol, vol.7, issue.1, pp.15-20, 2004.

C. Rummel, W. Kissling, and S. Leucht, Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev, p.5581, 2006.

S. P. Singh, V. Singh, N. Kar, and K. Chan, Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis, Br J Psychiatry, vol.197, issue.3, pp.174-183, 2010.

A. A. Sepehry, S. Potvin, R. Elie, and E. Stip, Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis, J Clin Psychiatry, vol.68, issue.4, pp.604-614, 2007.

T. Barnes and C. Paton, Do antidepressants improve negative symptoms in schizophrenia?, BMJ, vol.342, p.3371, 2011.

M. Yassini, N. Shariat, M. Nadi, F. Amini, and M. Vafaee, The effects of bupropion on negative symptoms in schizophrenia, Iran J Pharm Res IJPR, vol.13, issue.4, pp.1227-1260, 2014.

S. Shafti, S. Jafarabad, M. S. Azizi, and R. , Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor, Ther Adv Psychopharmacol, vol.5, issue.5, pp.263-70, 2015.

L. A. Perry, D. Ramson, and S. Stricklin, Mirtazapine adjunct for people with schizophrenia, Cochrane Database Syst Rev, vol.5, p.11943, 201826.

J. A. Lieberman, J. M. Kane, and J. Alvir, Provocative tests with psychostimulant drugs in schizophrenia, Psychopharmacology (Berl), vol.91, issue.4, pp.415-448, 1987.

J. W. Tossell, D. K. Greenstein, A. L. Davidson, S. B. Job, P. Gochman et al., Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series, J Child Adolesc Psychopharmacol, vol.14, issue.3, pp.448-54, 2004.

J. Lindenmayer, H. Nasrallah, M. Pucci, S. James, and L. Citrome, A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities, Schizophr Res, vol.147, issue.2-3, pp.241-52, 2013.

S. Shafti, S. Akbari, and S. , Intractability of Deficit Syndrome of Schizophrenia Against Adjunctive Modafinil, J Clin Psychopharmacol, vol.36, issue.1, pp.45-54, 2016.

R. A. Lasser, B. Dirks, H. Nasrallah, C. Kirsch, J. Gao et al., Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases, Neuropsychopharmacology, vol.38, issue.11, pp.2140-2149, 2013.

J. Tiihonen, K. Wahlbeck, and V. Kiviniemi, The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis, Schizophr Res, vol.109, issue.1-3, pp.10-14, 2009.

D. C. Goff, Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Curr Opin Psychiatry, vol.28, pp.207-222, 2015.

S. P. Singh and V. Singh, Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia, CNS Drugs, vol.25, issue.10, pp.859-85, 2011.

G. E. Tsai and P. Lin, Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis, Curr Pharm Des, vol.16, issue.5, pp.522-559, 2010.

J. T. Kantrowitz, S. W. Woods, E. Petkova, B. Cornblatt, C. M. Corcoran et al., D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial, Lancet Psychiatry, vol.2, issue.5, pp.403-415, 2015.

M. C. Davis, W. P. Horan, and S. R. Marder, Psychopharmacology of the negative symptoms: current status and prospects for progress, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.5, pp.788-99, 2014.

P. Singer, S. Dubroqua, and B. K. Yee, Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?, Curr Pharm Des, vol.21, issue.26, pp.3771-87, 2015.

F. Rezaei, M. Mohammad-karimi, S. Seddighi, A. Modabbernia, M. Ashrafi et al., Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study, J Clin Psychopharmacol, vol.33, issue.3, pp.336-378, 2013.

C. Andrade, Memantine as an Augmentation Treatment for Schizophrenia: Limitations of Meta-Analysis for Evidence-Based Evaluation of Research, J Clin Psychiatry, vol.78, issue.9, pp.1307-1316, 2017.

S. Ribeiz, D. P. Bassitt, J. A. Arrais, R. Avila, D. C. Steffens et al., Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature, CNS Drugs, vol.24, issue.4, pp.303-320, 2010.

J. Singh, K. Kour, and M. B. Jayaram, Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev, vol.1, p.7967, 2012.

K. Choi, T. Wykes, and M. M. Kurtz, Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy, Br J Psychiatry, vol.203, issue.3, pp.172-180, 2013.

C. J. Schmidt, S. M. Sorensen, J. H. Kehne, A. A. Carr, and M. G. Palfreyman, The role of 5-HT2A receptors in antipsychotic activity, Life Sci, vol.56, issue.25, pp.2209-2231, 1995.

S. J. Duinkerke, P. A. Botter, A. A. Jansen, P. A. Van-dongen, A. J. Van-haaften et al., Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial, Br J Psychiatry J Ment Sci, vol.163, pp.451-456, 1993.

S. Akhondzadeh, M. Malek-hosseini, A. Ghoreishi, M. Raznahan, and S. Rezazadeh, Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study, Prog Neuropsychopharmacol Biol Psychiatry, vol.32, issue.8, pp.1879-83, 2008.

T. Kishi, T. Mukai, Y. Matsuda, and N. Iwata, Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review, Neuromolecular Med, vol.16, issue.1, pp.61-70, 2014.

G. Remington and M. V. Seeman, Schizophrenia and the influence of male gender, Clin Pharmacol Ther, vol.98, issue.6, pp.578-81, 2015.

Y. Shirayama, K. Hashimoto, Y. Suzuki, and T. Higuchi, Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia, Schizophr Res, vol.58, issue.1, pp.69-74, 2002.

M. S. Ritsner, H. Bawakny, and A. Kreinin, Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on twocenter trial, Psychiatry Clin Neurosci, vol.68, issue.6, pp.432-472, 2014.

A. Kardashev, Y. Ratner, and M. S. Ritsner, Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial, Clin Schizophr Relat Psychoses, vol.12, issue.1, pp.31-41, 2018.

J. Usall, E. Huerta-ramos, J. Labad, J. Cobo, C. Núñez et al., Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial, Schizophr Bull, vol.42, issue.2, pp.309-326, 2016.

K. Oya, Y. Matsuda, S. Matsunaga, T. Kishi, and N. Iwata, Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials, Eur Arch Psychiatry Clin Neurosci, vol.266, issue.5, pp.439-50, 2016.

N. Müller, E. Weidinger, B. Leitner, and M. J. Schwarz, The role of inflammation in schizophrenia, Front Neurosci, vol.9, p.372, 2015.

K. Oya, T. Kishi, and N. Iwata, Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials, Hum Psychopharmacol, vol.29, issue.5, pp.483-91, 2014.

R. W. Buchanan, J. Kreyenbuhl, D. L. Kelly, J. M. Noel, D. L. Boggs et al., Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, vol.36, pp.71-93, 2009.

R. Prikryl and H. P. Kucerova, Can repetitive transcranial magnetic stimulation be considered effective treatment option for negative symptoms of schizophrenia?, J ECT, vol.29, issue.1, pp.67-74, 2013.

C. Shi, X. Yu, E. Cheung, D. Shum, and R. Chan, Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis, Psychiatry Res, vol.215, issue.3, pp.505-518, 2014.

O. Elis, J. M. Caponigro, and A. M. Kring, Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions, Clin Psychol Rev, vol.33, issue.8, pp.914-942, 2013.

L. B. Dixon, F. Dickerson, A. S. Bellack, M. Bennett, D. Dickinson et al., Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements, vol.36, pp.48-70, 2009.

E. Velthorst, M. Koeter, M. Van-der-gaag, D. H. Nieman, A. Fett et al., Adapted cognitivebehavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression, Psychol Med, vol.45, issue.3, pp.453-65, 2015.

E. Tatsumi, K. Yotsumoto, T. Nakamae, and T. Hashimoto, Effects of occupational therapy on hospitalized chronic schizophrenia patients with severe negative symptoms, Kobe J Med Sci, vol.57, issue.4, pp.145-154, 2012.

D. T. Turner, M. Van-der-gaag, E. Karyotaki, and P. Cuijpers, Psychological interventions for psychosis: a meta-analysis of comparative outcome studies, Am J Psychiatry, vol.171, issue.5, pp.523-561, 2014.

A. Aleman, T. M. Lincoln, R. Bruggeman, I. Melle, J. Arends et al., Treatment of negative symptoms: Where do we stand, and where do we go?, Schizophr Res, vol.186, pp.55-62, 2017.

D. I. Velligan, D. Roberts, J. Mintz, N. Maples, X. Li et al., A randomized pilot study of MOtiVation and Enhancement training (MOVE) for negative symptoms in schizophrenia, Schizophr Res, vol.165, issue.0, pp.175-80, 2015.

G. E. Hogarty, S. Flesher, R. Ulrich, M. Carter, D. Greenwald et al., Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior. Arch Gen Psychiatry, vol.61, pp.866-76, 2004.

M. Pavlicevic, C. Trevarthen, and J. Duncan, Improvisational music therapy and the rehabilitation of persons suffering from chronic schizophrenia, J Music Ther, vol.31, issue.2, pp.86-104, 1994.

D. G. Dyck, R. A. Short, M. S. Hendryx, D. Norell, M. Myers et al., Management of negative symptoms among patients with schizophrenia attending multiple-family groups, Psychiatr Serv Wash DC, vol.51, issue.4, pp.513-522, 2000.

J. Azorin, M. Adida, R. Belzeaux, D. Pringuey, J. Franchi et al., Symptômes négatifs de la schizophrénie : approches psychothérapeutiques. L'Encéphale, vol.41, pp.6-57, 2015.

D. P. Johnson, D. L. Penn, B. L. Fredrickson, A. M. Kring, P. S. Meyer et al., A pilot study of loving-kindness meditation for the negative symptoms of schizophrenia, Schizophr Res, vol.129, issue.2-3, pp.137-177, 2011.

J. Favrod, F. Giuliani, F. Ernst, and C. Bonsack, Anticipatory pleasure skills training: a new intervention to reduce anhedonia in schizophrenia, Perspect Psychiatr Care, vol.46, issue.3, pp.171-81, 2010.

P. Johnstone and G. Zolese, Length of hospitalisation for people with severe mental illness, Cochrane Database Syst Rev, vol.2, p.384, 2000.

B. Mancevski, J. Keilp, M. Kurzon, R. M. Berman, V. Ortakov et al., Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia, Psychopathology, vol.40, issue.2, pp.83-92, 2007.

K. Llerena, S. G. Park, and J. M. Maccarthy, The Motivation and Pleasure Scale Self-Report (MAP-SR): Reliability and validity of a self-report measure of negative symptoms, Compr Psychiatry, vol.54, issue.5, pp.568-574, 2013.

A. Bemebenek, E. Schaeffet, and J. Wciorka, Assessment and self-assessment of patients'' attidudes troward their psychotic disorders, Psychiatr Pol, vol.31, issue.3, pp.47-48, 1997.

H. Ascher-svanum, S. Rochford, and D. Cisco, Patient education about schizophrenia: initial expectations and later satisfaction, Issues Ment Health Nurs, vol.22, issue.3, pp.3325-333, 2001.

S. Dollfus, C. Delouche, C. Hervochon, C. Mach, V. Bourgeois et al., Specificity and sensitivity of the Self-assessment of Negative Symptoms (SNS) in patients with schizophrenia, Schizophr Res, vol.211, pp.51-56, 2019.

J. E. Overall and D. R. Gorham, The Brief Psychiatric Rating Scale, Psychol Rep, vol.10, issue.3, pp.799-812, 1962.

, Communiqué de presse : La variabilité de la prise en charge de la schizophrénie dans les établissements de santé en 2011 -IRDES, 2018.

M. Horn, G. Vaiva, and A. Dumais, Drug management of agitation in emergency departments: theoretical recommendations and studies of practices
URL : https://hal.archives-ouvertes.fr/hal-02447574

, Presse Medicale Paris Fr, vol.44, issue.1, pp.20-26, 1983.

F. Baylé, O. Blanc, I. De-chazeron, J. Lesturgeon, C. Lançon et al.,

. L'encephale, , vol.37, pp.83-89, 2011.

M. Stein, D. E. Dietrich, M. W. Agelink, W. Becker, C. Chrysanthou et al., Naturalistic pharmacotherapy of acute episodes of schizophrenic disorders in comparison to treatment guidelines, Pharmacopsychiatry, vol.45, issue.5, pp.189-95, 2012.

V. Danivas and G. Venkatasubramanian, Current perspectives on chlorpromazine equivalents: Comparing apples and oranges!, Indian J Psychiatry, vol.55, issue.2, pp.207-215, 2013.

, Benzodiazepine Equivalence Table, 2018.

S. W. Woods, Chlorpromazine equivalent doses for the newer atypical antipsychotics, J Clin Psychiatry, vol.64, issue.6, pp.663-670, 2003.

A. F. Lehman, J. A. Lieberman, L. B. Dixon, T. H. Mcglashan, A. L. Miller et al., Practice Guideline for the Treatment of Partients with Schizophrenia, Second Edition, SUPPL.). Available, vol.from, issue.2, p.132, 2004.

D. Damien,

P. Chue, M. Eerdekens, I. Augustyns, B. Lachaux, P. Mol?an et al., Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets, Eur Neuropsychopharmacol, vol.15, issue.1, pp.111-118, 2005.

R. K. Nayak, D. R. Doose, and N. P. Nair, The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients, J Clin Pharmacol, vol.27, issue.2, pp.144-50, 1987.

G. Rekhi, W. Y. Ng, and J. Lee, Clinical utility of the Calgary Depression Scale for Schizophrenia in individuals at ultra-high risk of psychosis, Schizophr Res, 2017.

C. Hervochon, V. Bourgeois, M. Rotharmel, J. Duboc, L. Goff et al.,

. L'encephale, , 2017.

L. San, M. Bernardo, A. Gómez, P. Martínez, B. González et al., Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients, Nord J Psychiatry, vol.67, issue.1, pp.22-31, 2013.

P. Kulhara and K. Chandiramani, Positive and negative subtypes of schizophrenia. A follow-up study from India, Schizophr Res, vol.3, issue.2, pp.107-123, 1990.

M. R. Phillips, Z. Zhao, X. Xiong, X. Cheng, G. Sun et al., Changes in the Positive and Negative Symptoms of Schizophrenic In-patients in China, Br J Psychiatry, vol.159, issue.2, pp.226-257, 1991.

K. T. Mueser, M. S. Douglas, A. S. Bellack, and R. L. Morrison, Assessment of enduring deficit and negative symptom subtypes in schizophrenia, Schizophr Bull, vol.17, issue.4, pp.565-82, 1991.

M. Savill, C. Banks, H. Khanom, and S. Priebe, Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data, Psychol Med, vol.45, issue.8, pp.1613-1640, 2015.

G. Mezquida, B. Cabrera, M. Bioque, S. Amoretti, A. Lobo et al., The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study, Schizophr Res, vol.189, pp.84-90, 2017.

S. Dollfus and M. Petit, Negative symptoms in schizophrenia: their evolution during an acute phase, Schizophr Res, vol.17, issue.2, pp.187-94, 1995.

G. P. Strauss and J. M. Gold, A Psychometric Comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale, Schizophr Bull, vol.42, issue.6, pp.1384-94, 2016.

M. F. Pogue-geile and M. Harrow, Negative symptoms in schizophrenia: their longitudinal course and prognostic importance, Schizophr Bull, vol.11, issue.3, pp.427-466, 1985.

J. Addington and D. Addington, Positive and negative symptoms of schizophrenia: Their course and relationship over time, Schizophr Res, vol.5, issue.1, pp.51-60, 1991.

P. Wang and T. Si, Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry, vol.25, pp.134-174, 2013.

M. Large, K. Mullin, P. Gupta, A. Harris, and O. Nielssen, Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use, Aust N Z J Psychiatry, vol.48, issue.5, pp.418-450, 2014.

D. Capdevielle, J. Boulenger, D. Villebrun, and K. Ritchie, Durées d'hospitalisation des patients souffrant de schizophrénie : implication des systèmes de soin et conséquences médicoéconomiques. L'Encéphale, vol.35, pp.394-403, 2009.

D. Capdevielle, K. Ritchie, D. Villebrun, and J. Boulenger, Durées d'hospitalisation des patients souffrant de schizophrénie : facteurs cliniques de variations et leurs conséquences. L'Encéphale, vol.35, pp.90-96, 2009.